Abstract：
Glioblastoma multiforme (GBM) presents significant challenges in treatment, with current standard-of-care approaches offering limited efficacy and survival benefits. This necessitates the development of innovative therapeutic strategies to enhance treatment outcomes. Nanotechnology has emerged as a promising avenue in cancer therapy, offering targeted drug delivery and enhanced therapeutic efficacy. Polymeric nanoparticles, particularly those based on Poly (lactic-co-glycolic acid) (PLGA), have gained traction as drug carriers due to their biocompatibility and controlled release properties. However, their interception by macrophages poses challenges to effective drug delivery. Superparamagnetic iron oxide (SPIO) nanoparticles have shown promise as radiosensitizers, enhancing the efficacy of radiotherapy through the generation of reactive oxygen species (ROS). Moreover, cell membrane biomimetic drug delivery systems have garnered attention for their ability to improve biocompatibility and targeting capabilities. Leveraging these concepts, our study introduces a novel multifunctional platform, GM@P (T/S), comprising polymeric nanoparticles coated with cancer cell membrane. By encapsulating temozolomide (TMZ) and SPIO nanoparticles within GM@P (T/S), we aim to synergistically enhance the cytotoxic effects of chemotherapy and radiotherapy against GBM while overcoming limitations associated with conventional treatments. This innovative approach holds promise for addressing the unmet clinical needs in GBM therapy and advancing towards more effective and personalized treatment strategies.
摘要：
多形性胶质母细胞瘤（GBM）在治疗中提出了重大挑战，目前的标准治疗方法提供有限的疗效和生存益处。这就需要开发创新的治疗策略来提高治疗效果。纳米技术已经成为癌症治疗的一个有希望的途径，提供靶向药物递送和增强的治疗效果。聚合物纳米粒子,特别是基于聚（乳酸-乙醇酸共聚物）（PLGA）的那些，由于其生物相容性和控释性能，已获得作为药物载体的牵引力。然而,巨噬细胞对它们的拦截对有效的药物输送提出了挑战。超顺磁性氧化铁（SPIO）纳米粒子已显示出作为放射增敏剂的前景，通过产生活性氧（ROS）增强放疗的疗效。此外，细胞膜仿生药物递送系统因其提高生物相容性和靶向能力的能力而备受关注。利用这些概念，我们的研究引入了一个新颖的多功能平台，GM@P(T/S),包含涂覆有癌细胞膜的聚合物纳米颗粒。通过将替莫唑胺（TMZ）和SPIO纳米颗粒封装在GM@P（T/S）中，我们的目标是协同增强化疗和放疗对GBM的细胞毒性效应,同时克服与常规治疗相关的局限性.这种创新方法有望解决GBM治疗中未满足的临床需求，并朝着更有效和个性化的治疗策略迈进。
